A Study of Pembrolizumab in Combination with Investigational Agents in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Trial Identifier: 9999-01B
Sponsor: MSD
Start Date: January 2025
Primary Completion Date: June 2029
Study Completion Date: June 2029
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English

Trial Locations

Country Location
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03080
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Taiwan, Taipei Taipei, Taiwan, 10002
United States, CT New Haven, CT, United States, 06510
United States, IA Iowa City, IA, United States, 52242
United States, MO Kansas City, MO, United States, 64108
United States, ND Fargo, ND, United States, 58122
United States, NJ New Brunswick, NJ, United States, 08903
United States, NY Valhalla, NY, United States, 10595
United States, PA Philadelphia, PA, United States, 19104
United States, SD Sioux Falls, SD, United States, 57105
United States, UT Salt Lake City, UT, United States, 84113